ºù«ÍÞÊÓƵ's diagnostic portfolio has reached new heights with the of the first commercially available laboratory blood test to help evaluate traumatic brain injuries (TBIs), including concussions.
The test, which runs on ºù«ÍÞÊÓƵ’s  already in use in a significant number of labs across the United States, measures two biomarkers in the blood that are tightly correlated to brain injury. Reliable results are generated in as few as 18 minutes, and a negative result helps rule out the need for a CT scan.
Concussion evaluation has been substantively unchanged since the Glasgow Coma Scale was introduced in 1974, making ºù«ÍÞÊÓƵ’s blood test a game-changer that could ultimately transform the standard of care due to its speed, accuracy and objectivity.
Leading the Industry
This latest clearance complements ºù«ÍÞÊÓƵ’s i-STAT TBI Plasma test, the first rapid blood test on a portable analyzer to help evaluate mild TBI, which received FDA clearance in 2021. Now, however, TBI blood tests can be run on the high-throughput Alinity i, which will broaden access and allow clinicians to quickly assess individuals with mild TBIs. Having a blood test available could help reduce the number of unnecessary CT scans .
This test puts ºù«ÍÞÊÓƵ at the forefront of diagnostic innovation and reinforces its position as a leader in TBI testing.
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Share